Literature DB >> 18499212

The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.

John P Donahue1, Michael L Vetter, Nizar A Mukhtar, Richard T D'Aquila.   

Abstract

The HIV-1 virion infectivity factor (Vif) is required during viral replication to inactivate the host cell anti-viral factor, APOBEC3G (A3G). Vif binds A3G and a Cullin5-ElonginBC E3 ubiquitin ligase complex which results in the proteasomal degradation of A3G. The Vif PPLP motif (amino acids 161-164) is essential for normal Vif function because mutations in this motif reduce the infectivity of virions produced in T-cells. In this report, we demonstrate that mutation of the Vif PPLP motif reduces Vif binding to A3G without affecting its interaction with ElonginC and Cullin5. We demonstrate that the failure of the Vif mutant to bind A3G resulted in A3G incorporation into assembling virions with loss of viral infectivity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18499212      PMCID: PMC2474554          DOI: 10.1016/j.virol.2008.04.017

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  Hypermutation of HIV-1 DNA in the absence of the Vif protein.

Authors:  Denise Lecossier; Francine Bouchonnet; François Clavel; Allan J Hance
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

2.  Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.

Authors:  Bin Yang; Ling Gao; Lin Li; Zhixian Lu; Xuejun Fan; Charvi A Patel; Roger J Pomerantz; Garrett C DuBois; Hui Zhang
Journal:  J Biol Chem       Date:  2002-12-11       Impact factor: 5.157

3.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells.

Authors:  Yves Durocher; Sylvie Perret; Amine Kamen
Journal:  Nucleic Acids Res       Date:  2002-01-15       Impact factor: 16.971

5.  Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process.

Authors:  H Zhang; R J Pomerantz; G Dornadula; Y Sun
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle.

Authors:  S Yang; Y Sun; H Zhang
Journal:  J Biol Chem       Date:  2000-11-08       Impact factor: 5.157

7.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

8.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.

Authors:  Hui Zhang; Bin Yang; Roger J Pomerantz; Chune Zhang; Shyamala C Arunachalam; Ling Gao
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

9.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

10.  The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G.

Authors:  James H Miller; Vlad Presnyak; Harold C Smith
Journal:  Retrovirology       Date:  2007-11-24       Impact factor: 4.602

View more
  41 in total

Review 1.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

2.  HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Authors:  Iris Cadima-Couto; Nuno Saraiva; Ana Catarina C Santos; Joao Goncalves
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-29       Impact factor: 4.147

3.  Dissection of the HIV Vif interaction with human E3 ubiquitin ligase.

Authors:  Leslie S Wolfe; Bradford J Stanley; Chang Liu; William K Eliason; Yong Xiong
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

4.  Structural Insights into HIV-1 Vif-APOBEC3F Interaction.

Authors:  Masaaki Nakashima; Hirotaka Ode; Takashi Kawamura; Shingo Kitamura; Yuriko Naganawa; Hiroaki Awazu; Shinya Tsuzuki; Kazuhiro Matsuoka; Michiko Nemoto; Atsuko Hachiya; Wataru Sugiura; Yoshiyuki Yokomaku; Nobuhisa Watanabe; Yasumasa Iwatani
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

5.  APOBEC3G complexes decrease human immunodeficiency virus type 1 production.

Authors:  Kenneth L Martin; Megan Johnson; Richard T D'Aquila
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

6.  Hydrodynamic and functional analysis of HIV-1 Vif oligomerization.

Authors:  Stephen M Techtmann; Rodolfo Ghirlando; Sandra Kao; Klaus Strebel; Ernest L Maynard
Journal:  Biochemistry       Date:  2012-03-05       Impact factor: 3.162

Review 7.  Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.

Authors:  Jessica L Smith; Wei Bu; Ryan C Burdick; Vinay K Pathak
Journal:  Trends Pharmacol Sci       Date:  2009-12       Impact factor: 14.819

8.  The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex.

Authors:  Julien R C Bergeron; Hendrik Huthoff; Dennis A Veselkov; Rebecca L Beavil; Peter J Simpson; Stephen J Matthews; Michael H Malim; Mark R Sanderson
Journal:  PLoS Pathog       Date:  2010-06-03       Impact factor: 6.823

9.  Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif.

Authors:  Anne Piantadosi; Daryl Humes; Bhavna Chohan; R Scott McClelland; Julie Overbaugh
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

10.  A proposed syntax for Minimotif Semantics, version 1.

Authors:  Jay Vyas; Ronald J Nowling; Mark W Maciejewski; Sanguthevar Rajasekaran; Michael R Gryk; Martin R Schiller
Journal:  BMC Genomics       Date:  2009-08-05       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.